{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:02:30Z","timestamp":1789549350330,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014476","name":"Pfizer Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare real-world effectiveness of tofacitinib monotherapy to adalimumab monotherapy, and tofacitinib and adalimumab in combination with csDMARDs in Rheumatoid Arthritis (RA) subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Retrospective routine care data was used from six Dutch cohorts for RA patients who initiated tofacitinib or adalimumab between 2001 and 2022. Drug survival of tofacitinib monotherapy (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009229) was compared with that of tofacitinib combination-therapy (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009179), adalimumab monotherapy (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091019) and adalimumab combination-therapy (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091361) using Kaplan\u2013Meier curves and Cox regression. Drug survival was evaluated as an indirect measure of treatment persistence. Exploratory analyses assessed effect modifications by anti-citrullinated protein antibody (ACPA) status and age at treatment onset in both models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients who started tofacitinib monotherapy were older compared to other treatment groups (61 vs 55, 58 and 58 years) and had used at least one previous b\/tsDMARD more often compared to the adalimumab treatment groups (36% vs 41%, 19% and 13%). Compared to tofacitinib monotherapy, the risk of drug discontinuation was similar for tofacitinib combination-therapy (aHR 1.22, 95% CI: 0.96\u20131.54) and adalimumab monotherapy (aHR 0.89, 95% CI: 0.73\u20131.09) but lower for adalimumab combination-therapy (aHR 0.78, 95% CI: 0.63\u20130.96). Older age was associated with significantly higher risk of drug discontinuation. No effect modification by ACPA was observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Based on real-world data from six Dutch cohorts, drug discontinuation was higher for tofacitinib than for adalimumab, with similar outcomes with or without csDMARDs. Older age was associated with a higher risk of drug discontinuation independently of treatment group, although this finding may be influenced by factors beyond treatment effectiveness.\n                      <jats:table-wrap>\n                        <jats:table>\n                          <jats:tbody>\n                            <jats:tr>\n                              <jats:td colspan=\"2\">\n                                <jats:bold>Key Points<\/jats:bold>\n                                \u2022\n                                <jats:italic>In a real-world setting tofacitinib was observed to have similar drug survival in mono- and combination therapy<\/jats:italic>\n                                \u2022\n                                <jats:italic>ACPA status did not influence drug survival<\/jats:italic>\n                                \u2022\u00a0\n                                <jats:italic>Older age was related to a higher risk of drug discontinuation independently of treatment<\/jats:italic>\n                              <\/jats:td>\n                            <\/jats:tr>\n                          <\/jats:tbody>\n                        <\/jats:table>\n                      <\/jats:table-wrap>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10067-026-08362-x","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T13:43:05Z","timestamp":1787146985000},"page":"6071-6080","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world effectiveness of tofacitinib in monotherapy or in combination with csDMARDs in patients with rheumatoid arthritis: A collaboration between Dutch registries (TOFADUDAP study)"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6936-5217","authenticated-orcid":false,"given":"Isabell S.","family":"Nevins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman Kasper","family":"Glas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floor","family":"Reimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke P. D.","family":"de Buck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Wiepke","family":"Drossaers-Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam C.","family":"Hegeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom W. J.","family":"Huizinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sytske Anne","family":"Bergstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"issue":"1","key":"8362_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS et al (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82(1):3\u201318","journal-title":"Ann Rheum Dis"},{"issue":"10093","key":"8362_CR2","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R et al (2017) Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet 390(10093):457\u2013468","journal-title":"Lancet"},{"issue":"7","key":"8362_CR3","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC et al (2017) Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 376(7):652\u2013662","journal-title":"N Engl J Med"},{"issue":"6","key":"8362_CR4","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF van Vollenhoven","year":"2012","unstructured":"van Vollenhoven RF et al (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367(6):508\u201319","journal-title":"N Engl J Med"},{"issue":"2","key":"8362_CR5","first-page":"318","volume":"34","author":"JA Hodge","year":"2016","unstructured":"Hodge JA et al (2016) The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 34(2):318\u2013328","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"8362_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"FC Breedveld","year":"2006","unstructured":"Breedveld FC et al (2006) The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54(1):26\u201337","journal-title":"Arthritis Rheum"},{"issue":"9410","key":"8362_CR7","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","volume":"363","author":"L Klareskog","year":"2004","unstructured":"Klareskog L et al (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363(9410):675\u2013681","journal-title":"Lancet"},{"issue":"2","key":"8362_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000491","volume":"3","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R et al (2017) Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies. RMD Open 3(2)","journal-title":"RMD Open"},{"issue":"4","key":"8362_CR9","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/art.21655","volume":"54","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde D et al (2006) Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 54(4):1063\u201374","journal-title":"Arthritis Rheum"},{"issue":"6","key":"8362_CR10","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1136\/ard.2008.099010","volume":"68","author":"EC Keystone","year":"2009","unstructured":"Keystone EC et al (2009) Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 68(6):789\u2013796","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"8362_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177057","volume":"12","author":"N Iwamoto","year":"2017","unstructured":"Iwamoto N et al (2017) Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis. PLoS ONE 12(5)","journal-title":"PLoS ONE"},{"key":"8362_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001174","author":"A Finckh","year":"2020","unstructured":"Finckh A et al (2020) Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2020-001174","journal-title":"RMD Open"},{"issue":"1","key":"8362_CR13","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3906\/sag-2007-123","volume":"51","author":"E Bilgin","year":"2021","unstructured":"Bilgin E et al (2021) Efficacy, retention, and safety of tofacitinib in real-life: Hur-bio monocentric experience. Turk J Med Sci 51(1):297\u2013308","journal-title":"Turk J Med Sci"},{"issue":"4","key":"8362_CR14","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s40744-019-00177-4","volume":"6","author":"GW Reed","year":"2019","unstructured":"Reed GW et al (2019) Real-world comparative effectiveness of tofacitinib and tumor necrosis factor inhibitors as monotherapy and combination therapy for treatment of rheumatoid arthritis. Rheumatol Ther 6(4):573\u2013586","journal-title":"Rheumatol Ther"},{"issue":"9","key":"8362_CR15","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/rheumatology\/kev019","volume":"54","author":"C Gabay","year":"2015","unstructured":"Gabay C et al (2015) Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry. Rheumatology (Oxford) 54(9):1664\u20131672","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"8362_CR16","first-page":"523","volume":"55","author":"A Souto","year":"2016","unstructured":"Souto A, Maneiro JR, Gomez-Reino JJ (2016) Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology (Oxford) 55(3):523\u2013534","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"8362_CR17","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1093\/rheumatology\/kez221","volume":"58","author":"K Lauper","year":"2019","unstructured":"Lauper K et al (2019) Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution. Rheumatology (Oxford) 58(12):2221\u20132229","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"8362_CR18","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.3899\/jrheum.111125","volume":"39","author":"F Iannone","year":"2012","unstructured":"Iannone F et al (2012) Longterm retention of tumor necrosis factor-alpha inhibitor therapy in a large Italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol 39(6):1179\u20131184","journal-title":"J Rheumatol"},{"issue":"5","key":"8362_CR19","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/03009742.2016.1234641","volume":"46","author":"KJ Aaltonen","year":"2017","unstructured":"Aaltonen KJ et al (2017) Drug survival on tumour necrosis factor inhibitors in patients with rheumatoid arthritis in Finland. Scand J Rheumatol 46(5):359\u2013363","journal-title":"Scand J Rheumatol"},{"issue":"7","key":"8362_CR20","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrd3501","volume":"10","author":"HG Eichler","year":"2011","unstructured":"Eichler HG et al (2011) Bridging the efficacy-effectiveness gap: a regulator\u2019s perspective on addressing variability of drug response. Nat Rev Drug Discov 10(7):495\u2013506","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"8362_CR21","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/art.37816","volume":"65","author":"D van der Heijde","year":"2013","unstructured":"van der Heijde D et al (2013) Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 65(3):559\u2013570","journal-title":"Arthritis Rheum"},{"issue":"6","key":"8362_CR22","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R et al (2012) Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367(6):495\u2013507","journal-title":"N Engl J Med"},{"issue":"6","key":"8362_CR23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.20851","volume":"6","author":"CT Deakin","year":"2023","unstructured":"Deakin CT et al (2023) Comparative effectiveness of adalimumab vs tofacitinib in patients with rheumatoid arthritis in Australia. JAMA Netw Open 6(6)","journal-title":"JAMA Netw Open"},{"issue":"1","key":"8362_CR24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41598-021-04075-0","volume":"12","author":"K Ebina","year":"2022","unstructured":"Ebina K et al (2022) Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. Sci Rep 12(1):134","journal-title":"Sci Rep"},{"issue":"1","key":"8362_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-44841-w","volume":"13","author":"M Riek","year":"2023","unstructured":"Riek M et al (2023) Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care. Sci Rep 13(1)","journal-title":"Sci Rep"},{"issue":"2","key":"8362_CR26","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/acr2.1010","volume":"1","author":"JE Pope","year":"2019","unstructured":"Pope JE et al (2019) Persistence of tofacitinib in the treatment of rheumatoid arthritis in open-label, long-term extension studies up to 9.5 years. ACR Open Rheumatol 1(2):73\u201382","journal-title":"ACR Open Rheumatol"},{"issue":"4","key":"8362_CR27","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nrrheum.2011.28","volume":"7","author":"NA Daha","year":"2011","unstructured":"Daha NA, Toes RE (2011) Rheumatoid arthritis: are ACPA-positive and ACPA-negative RA the same disease? Nat Rev Rheumatol 7(4):202\u2013203","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"8362_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/ar4540","volume":"16","author":"L Innala","year":"2014","unstructured":"Innala L et al (2014) Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study. Arthritis Res Ther 16(2)","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"8362_CR29","first-page":"256","volume":"31","author":"D Huscher","year":"2013","unstructured":"Huscher D et al (2013) Clinical presentation, burden of disease and treatment in young-onset and late-onset rheumatoid arthritis: a matched-pairs analysis taking age and disease duration into account. Clin Exp Rheumatol 31(2):256\u2013262","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"8362_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/ar4439","volume":"16","author":"SD Seegobin","year":"2014","unstructured":"Seegobin SD et al (2014) ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial. Arthritis Res Ther 16(1)","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"8362_CR31","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jbspin.2010.04.004","volume":"77","author":"M Soubrier","year":"2010","unstructured":"Soubrier M et al (2010) Elderly-onset rheumatoid arthritis. Joint Bone Spine 77(4):290\u2013296","journal-title":"Joint Bone Spine"},{"issue":"11","key":"8362_CR32","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1136\/annrheumdis-2020-217725","volume":"79","author":"M Greenwood","year":"2020","unstructured":"Greenwood M et al (2020) Methotrexate reduces withdrawal rates of TNF inhibitors due to ineffectiveness in rheumatoid arthritis but only in patients who are seropositive. Ann Rheum Dis 79(11):1516\u20131517","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"8362_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0250877","volume":"16","author":"CT Lin","year":"2021","unstructured":"Lin CT et al (2021) Predictors of drug survival for biologic and targeted synthetic DMARDs in rheumatoid arthritis: analysis from the TRA clinical electronic registry. PLoS ONE 16(4)","journal-title":"PLoS ONE"},{"issue":"1","key":"8362_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000742","volume":"5","author":"P Bird","year":"2019","unstructured":"Bird P et al (2019) Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in phase III randomised clinical trials of tofacitinib. RMD Open 5(1)","journal-title":"RMD Open"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08362-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08362-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08362-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:04:19Z","timestamp":1789545859000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08362-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["8362"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08362-x","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"assertion":[{"value":"8 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This cohort received a waiver from asking for informed consent. The cohort contains anonymized data which was gathered during daily practice. Treatment, timing of follow-up visits and measurements were not protocolled.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SAB has received a grant from Pfizer and speaker fees from Benecke. RB has received grants from Galapagos and Sanofi and consulting fees from Abbvie, Galapagos, Janssen, Pfizer and UCB. The other authors have disclosed no conflicts of interest.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}